Cancer Chemotherapy and Pharmacology

, Volume 70, Issue 5, pp 673–681 | Cite as

A phase I and pharmacokinetic study of elisidepsin (PM02734) in patients with advanced solid tumors

  • R. SalazarEmail author
  • R. J. Jones
  • A. Oaknin
  • D. Crawford
  • C. Cuadra
  • C. Hopkins
  • M. Gil
  • C. Coronado
  • A. Soto-Matos
  • M. Cullell-Young
  • J. L. Iglesias Dios
  • T. R. J. Evans
Original Article



To determine the maximum-tolerated dose (MTD), dose-limiting toxicity (DLT), and recommended phase II dose (RD) of elisidepsin.


Eligible patients with refractory, advanced solid tumors received elisidepsin as 24-h intravenous infusion every 3 weeks. Pharmacokinetic profiles were analyzed during cycles 1 and 2.


Forty-two patients received elisidepsin at doses from 0.5 to 6.8 mg/m2. The MTD was 6.8 mg/m2, and the RD was 5.5 mg/m2. Cohort expansion at the RD was done at a fixed dose (FD) of 10 mg, considered equivalent to 5.5 mg/m2. DLTs (reversible grade 3 transaminase increases) occurred at 6.8 mg/m2 (n = 2 patients), 5.5 mg/m2 (n = 1), and 10 mg FD (n = 1). One patient with esophageal adenocarcinoma achieved complete response for >38 months, and 12 patients had disease stabilization (8 for ≥3 months). Median time-to-progression for these 12 patients was 4.8 months. Plasma elisidepsin concentrations increased with dose. No drug accumulation between cycles was found. No correlation was observed between body surface area (BSA) and plasma clearance; therefore, elisidepsin was given as flat dose (in mg) in the expansion cohort at the RD and in ongoing clinical trials.


Elisidepsin is well tolerated with predictable reversible transaminase increases. Encouraging preliminary evidence of antitumor activity was observed.


Anti-proliferative Depsipeptide Kahalalide F Pharmacokinetics Phase I study 



The authors are grateful to the patients who participated in this study and to their carers. The authors also acknowledge the study research teams who contributed to this study at both participating centers. The study was supported at the Beatson West of Scotland Cancer Centre by the Glasgow Experimental Cancer Medicine Centre, which is funded by Cancer Research UK and by the Chief Scientist Office, Scotland.


  1. 1.
    Hamann MT, Otto CS, Scheuer PJ, Dunbar DC (1996) Kahalalides: bioactive peptides from a marine mollusk Elysia rufescens and its algal diet bryopsis sp. (1). J Org Chem 61:6594–6600PubMedCrossRefGoogle Scholar
  2. 2.
    Sparidans RW, Stokvis E, Jimeno JM, Lopez-Lazaro L, Schellens JH, Beijnen JH (2001) Chemical and enzymatic stability of a cyclic depsipeptide, the novel, marine-derived, anti-cancer agent kahalalide F. Anticancer Drugs 12:575–582PubMedCrossRefGoogle Scholar
  3. 3.
    Faircloth G, Cuevas C (2006) Kahalalide F and ES285: potent anticancer agents from marine molluscs. Prog Mol Subcell Biol 43:363–379PubMedCrossRefGoogle Scholar
  4. 4.
    Provencio M, Sanchez A, Gasent J, Gomez P, Rosell R (2009) Cancer treatments: can we find treasures at the bottom of the sea? Clin Lung Cancer 10:295–300PubMedCrossRefGoogle Scholar
  5. 5.
    Ling YH, Aracil M, Jimeno J, Perez-Soler R, Zou Y (2009) Molecular pharmacodynamics of PM02734 (elisidepsin) as single agent and in combination with erlotinib; synergistic activity in human non-small cell lung cancer cell lines and xenograft models. Eur J Cancer 45:1855–1864PubMedCrossRefGoogle Scholar
  6. 6.
    Elices M, Lepage DJ, Grant W, Alvarez E, Guillen MJ, Cuevas C, Aviles P, Faircloth G (2006) Activity of PM02734 against human breast and prostate tumors. Proc Am Assoc Cancer Res 47 (Abst. 4712)Google Scholar
  7. 7.
    Herrero AB, Astudillo AM, Balboa MA, Cuevas C, Balsinde J, Moreno S (2008) Levels of SCS7/FA2H-mediated fatty acid 2-hydroxylation determine the sensitivity of cells to antitumor PM02734. Cancer Res 68:9779–9787PubMedCrossRefGoogle Scholar
  8. 8.
    Molina-Guijarro JM, Moneo V, Martínez-Leal JF, Cuevas C, García-Fernández LF, Galmarini CM (2009) PM02734, a new marine-derived antitumoral compound, has rapid effects on membrane integrity and permeability in tumor cells. Paper presented at the proceedings of the 100th annual meeting of the American association for cancer researchGoogle Scholar
  9. 9.
    Coronado C, Galmarini CM, Alfaro V, Yovine A (2010) Elisidepsin. Drugs Fut 35:287–296CrossRefGoogle Scholar
  10. 10.
    Sasak H, Yin J, Elices M, LePage D, Cuevas Marchante C, Aviles P, Faircloth G (2006) PM02734 cytotoxicity in vitro and pharmacokinetics. Proc Am Assoc Cancer Res 47 (Abst. 1911)Google Scholar
  11. 11.
    Simon R, Freidlin B, Rubinstein L, Arbuck SG, Collins J, Christian MC (1997) Accelerated titration designs for phase I clinical trials in oncology. J Natl Cancer Inst 89:1138–1147PubMedCrossRefGoogle Scholar
  12. 12.
    Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205–216PubMedCrossRefGoogle Scholar
  13. 13.
    Yin J, Aviles P, Lee W, Ly C, Guillen MJ, Munt S, Cuevas C, Faircloth G (2006) Development of a liquid chromatography/tandem mass spectrometry assay for the quantification of PM02734, a novel antineoplastic agent, in dog plasma. Rapid Commun Mass Spectrom 20:2735–2740PubMedCrossRefGoogle Scholar
  14. 14.
    Bruce JY, Geary D, De las Heras B, Soto A, Garcia Paramio P, Yovine A, Schilsky RL, Undevia SD, Ratain MJ (2008) Phase I study of PM02734: association of dose-limiting hepatotoxicity with plasma concentrations. J Clin Oncol 26 (Abstract 2513)Google Scholar
  15. 15.
    Hama H, Young DA, Radding JA, Ma D, Tang J, Stock SD, Takemoto JY (2000) Requirement of sphingolipid alpha-hydroxylation for fungicidal action of syringomycin E. FEBS Lett 478:26–28PubMedCrossRefGoogle Scholar
  16. 16.
    Nyholm PG, Pascher I, Sundell S (1990) The effect of hydrogen bonds on the conformation of glycosphingolipids. Methylated and unmethylated cerebroside studied by X-ray single crystal analysis and model calculations. Chem Phys Lipids 52:1–10PubMedCrossRefGoogle Scholar
  17. 17.
    Brown DA, London E (1998) Functions of lipid rafts in biological membranes. Annu Rev Cell Dev Biol 14:111–136PubMedCrossRefGoogle Scholar
  18. 18.
    Molina-Guijarro JM, Macias A, Garcia C, Munoz E, Garcia-Fernandez LF, David M, Nunez L, Martinez-Leal JF, Moneo V, Cuevas C, Lillo MP, Villalobos Jorge C, Valenzuela C, Galmarini CM (2011) Irvalec inserts into the plasma membrane causing rapid loss of integrity and necrotic cell death in tumor cells. PLoS ONE 6:e19042PubMedCrossRefGoogle Scholar
  19. 19.
    Suarez Y, Gonzalez L, Cuadrado A, Berciano M, Lafarga M, Munoz A (2003) Kahalalide F, a new marine-derived compound, induces oncosis in human prostate and breast cancer cells. Mol Cancer Ther 2:863–872PubMedGoogle Scholar
  20. 20.
    Sewell JM, Mayer I, Langdon SP, Smyth JF, Jodrell DI, Guichard SM (2005) The mechanism of action of Kahalalide F: variable cell permeability in human hepatoma cell lines. Eur J Cancer 41:1637–1644PubMedCrossRefGoogle Scholar
  21. 21.
    Garcia-Rocha M, Bonay P, Avila J (1996) The antitumoral compound Kahalalide F acts on cell lysosomes. Cancer Lett 99:43–50PubMedCrossRefGoogle Scholar
  22. 22.
    Cruz LJ, Luque-Ortega JR, Rivas L, Albericio F (2009) Kahalalide F, an antitumor depsipeptide in clinical trials, and its analogues as effective antileishmanial agents. Mol Pharm 6:813–824PubMedCrossRefGoogle Scholar
  23. 23.
    Reuben A (2004) Hy’s law. Hepatology 39:574–578PubMedCrossRefGoogle Scholar
  24. 24.
    Temple R (2006) Hy’s law: predicting serious hepatotoxicity. Pharmacoepidemiol Drug Saf 15:241–243PubMedCrossRefGoogle Scholar
  25. 25.
    Coronado C, Kahatt C, Szyldergemajn S, Iglesias JL, Florez A, Yovine A (2010) Transient isolated transaminase increases do not correlate with permanent clinical liver damage: phase I experience with Elisidepsin. Ann Oncol 21:180–181Google Scholar
  26. 26.
    Rademaker-Lakhai JM, Horenblas S, Meinhardt W, Stokvis E, de Reijke TM, Jimeno JM, Lopez-Lazaro L, Lopez Martin JA, Beijnen JH, Schellens JH (2005) Phase I clinical and pharmacokinetic study of kahalalide F in patients with advanced androgen refractory prostate cancer. Clin Cancer Res 11:1854–1862PubMedCrossRefGoogle Scholar
  27. 27.
    Pardo B, Paz-Ares L, Tabernero J, Ciruelos E, Garcia M, Salazar R, Lopez A, Blanco M, Nieto A, Jimeno J, Izquierdo MA, Trigo JM (2008) Phase I clinical and pharmacokinetic study of kahalalide F administered weekly as a 1-hour infusion to patients with advanced solid tumors. Clin Cancer Res 14:1116–1123PubMedCrossRefGoogle Scholar
  28. 28.
    Martin-Algarra S, Espinosa E, Rubio J, Lopez Lopez JJ, Manzano JL, Carrion LA, Plazaola A, Tanovic A, Paz-Ares L (2009) Phase II study of weekly Kahalalide F in patients with advanced malignant melanoma. Eur J Cancer 45:732–735PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2012

Authors and Affiliations

  • R. Salazar
    • 1
    Email author
  • R. J. Jones
    • 2
  • A. Oaknin
    • 1
  • D. Crawford
    • 2
  • C. Cuadra
    • 1
  • C. Hopkins
    • 2
  • M. Gil
    • 1
  • C. Coronado
    • 3
  • A. Soto-Matos
    • 3
  • M. Cullell-Young
    • 3
  • J. L. Iglesias Dios
    • 3
  • T. R. J. Evans
    • 2
  1. 1.Instituto Catalán de OncologíaL’Hospitalet de LlobregatBarcelonaSpain
  2. 2.Beatson West of Scotland Cancer CentreThe University of GlasgowGlasgowUK
  3. 3.Pharma Mar, S.A. Sociedad UnipersonalMadridSpain

Personalised recommendations